热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 570™ anti-human CD8a Antibo
产品名称：
Brilliant Violet 570™ anti-human CD8a Antibo
产品类别：
抗体
产品编号：
301037
产品应用：
301037
[价格]
规格 价格 库存
25tests ￥ 2926 1

产品详情

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee, Baboon, Pigtailed Macaque, Sooty Mangabey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 570? under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Brilliant Violet 570? excites at 405 nm and emits at 570 nm. The bandpass filter 585/42 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 570? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections3 and costimulation of T cell responses4. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 301073 & 301074).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  4. Magidovich E, et al. 2007. P. Natl. Acad. Sci. USA 104:13022.
  5. Thakarl D, et al. 2008.J. immunol. 180:7431. PubMed
  6. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  7. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  10. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
Product Citations
  1. Bolton D, et al. 2016. J Virol. 90: 1321 - 1332. PubMed
  2. Tran TM, et al. 2020. Immunity. 51(4):750-765. PubMed
  3. Leeansyah E, et al. 2015. PLoS Pathog. 11: 1005072. PubMed
  4. Blasi M, et al. 2020. NPJ Vaccines. 5:36. PubMed
  5. Negri D, et al. 2016. Mol Ther. 24:2021-2032. PubMed
  6. Turner JS, et al. 2021. Nature. 596:109. PubMed
  7. Veenhuis RT, et al. 2021. JCI Insight. 6:. PubMed
  8. Romero-Olmedo AJ, et al. 2022. Nat Microbiol. 7:195. PubMed
  9. Gagne M, et al. 2022. Cell. 185:113. PubMed
  10. García-Arriaza J, et al. 2015. J Virol. 89: 8525-8539. PubMed
  11. Marquardt N, et al. 2019. Nat Commun. 10:3841. PubMed
  12. Liechti T, et al. 2022. Nat Commun. 13:7255. PubMed
  13. de Andrade LF, et al. 2019. JCI Insight. 4:e133103. PubMed
  14. Nishimura Y, et al. 2017. Nature. 543:559. PubMed
  15. Baier FA, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:745. PubMed
  16. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  17. Bradley T et al. 2018. Cell. 175(2):387-399 . PubMed
  18. Roberts E, et al. 2016. PLoS One. 11:e0168488. PubMed
  19. Swanstrom A, et al. 2016. J Virol. 90: 4966 - 4980. PubMed
  20. Vierboom MPM, et al. 2020. NPJ Vaccines. 5:39. PubMed
  21. Shifrut E et al. 2018. Cell. 175(7):1958-1971 . PubMed
  22. Hensley-McBain T, et al. 2016. J Virol. 90: 4981 - 4989. PubMed
  23. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  24. Bradley T, et al. 2020. Nat Commun. 11:948. PubMed
  25. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  26. Mold JE, et al. 2021. Cell Reports. 35(8):109174. PubMed
  27. Han Q, et al. 2020. Cell Rep. 30:1553. PubMed
  28. Kaustio M, et al. 2021. J Allergy Clin Immunol. 148:599. PubMed
  29. Maleki KT, et al. 2021. Cell Reports Medicine. 2(3):100220. PubMed
  30. Vierboom MPM, et al. 2020. NPJ Vaccines. 5:39. PubMed
  31. Blasi M, et al. 2020. NPJ Vaccines. 5:36. PubMed
  32. King HAD, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  33. Wilson TL, et al. 2022. Cancer Discov. 12:2098. PubMed
  34. Tauzin A, et al. 2021. Cell Host Microbe. . PubMed
  35. Mawa P, et al. 2015. Phil Trans R Soc B. 19:370. PubMed
  36. Luoma AM, et al. 2020. Cell. 182(3):655-671.e22. PubMed
  37. Darrah PA, et al. 2019. NPJ Vaccines. 4:21. PubMed
  38. Paquin-Proulx D, et al. 2016. J Immunol. 197: 1843 - 1851. PubMed
  39. Kang HM, et al. 2018. Nat Biotechnol. 36:89. PubMed
RRID
AB_10933259 (BioLegend Cat. No. 301037) AB_2563213 (BioLegend Cat. No. 301038)

Antigen Details

Structure
Ig superfamily, homodimer or heterodimer with CD8β, 32-34 kD
Distribution

Majority of thymocytes, T cell subset, NK cells

Function
MHC class I co-receptor, thymic differentiation, T cell activation
Ligand/Receptor
MHC Class I molecules
Cell Type
Dendritic cells, NK cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
925 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线